Listar por autor "Lazzarin, Adriano"
Mostrando ítems 1-12 de 12
-
96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures
Johnson, Margaret et al. | Fecha del documento: 2006 -
Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures.
Johnson, Margaret et al. | Fecha del documento: 2005 -
Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials
Clotet, Bonaventura et al. | Fecha del documento: 2007 -
Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials
Katlama, Christine et al. | Fecha del documento: 2009 -
Efficacy and safety of raltegravir for treatment of HIV for 5 years in the benchmrk studies: final results of two randomised, placebo-controlled trials
Eron, Joseph J. et al. | Fecha del documento: 2013 -
Long-term efficacy and safety of raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 phase III trials
Steigbigel, Roy T. et al. | Fecha del documento: 2010 -
Long-term efficacy and safety of the HIV integrase inhibitor raltegravir in patients with limited treatment options in a Phase II study
Gatell, Jose M et al. | Fecha del documento: 2010 -
Raltegravir with optimized background therapy for resistant HIV-1 infection
Steigbigel, Roy T. et al. | Fecha del documento: 2008 -
Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial
Molina, Jean-Michel et al. | Fecha del documento: 2011 -
Ritonavir-boosted tipranavir demonstrates superior efficacy to ritonavir-boosted protease inhibitors in treatment-experienced HIV-infected patients: 24-week results of the RESIST-2 trial
Cahn, Pedro et al. | Fecha del documento: 2006 -
Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial
Grinsztejn, Beatriz et al. | Fecha del documento: 2007 -
Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection
Cooper, David A. et al. | Fecha del documento: 2008